JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Home・Aandelen Lijst・CorMedix Inc

CorMedix Inc

Gesloten

SectorGezondheidszorg

10 -2.72

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.94

Max

10.27

Belangrijke statistieken
By Trading Economics
Inkomsten	7.2M 21M
Verkoop	7.9M 39M
K/W Sectorgemiddelde	45.815 34.393
Winstmarge	52.822
Werknemers	64
EBITDA	7.2M 21M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+86.2% upside

Dividenden
By Dow Jones
Volgende Winsten	29 okt 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	285M 921M
Vorige openingsprijs	12.72
Vorige sluitingsprijs	10

Nieuwssentiment

By Acuity

20%

80%

30 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

9.2 / N/A Steun & Weerstand

CorMedix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 aug 2025, 17:49 UTC

Belangrijke Marktbewegers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug 2025, 17:18 UTC

Belangrijke Marktbewegers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug 2025, 16:25 UTC

Winsten

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Global Energy Roundup: Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug 2025, 23:32 UTC

Marktinformatie

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug 2025, 23:02 UTC

Marktinformatie

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 aug 2025, 20:37 UTC

Winsten

Acquisities, Fusies, Overnames

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug 2025, 20:37 UTC

Winsten

Acquisities, Fusies, Overnames

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug 2025, 20:37 UTC

Winsten

Acquisities, Fusies, Overnames

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug 2025, 20:14 UTC

Marktinformatie

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug 2025, 19:12 UTC

Marktinformatie

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug 2025, 18:56 UTC

Marktinformatie

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug 2025, 18:31 UTC

Marktinformatie

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug 2025, 17:43 UTC

Marktinformatie

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug 2025, 17:28 UTC

Marktinformatie

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug 2025, 17:16 UTC

Marktinformatie

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug 2025, 16:42 UTC

Acquisities, Fusies, Overnames

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug 2025, 16:27 UTC

Acquisities, Fusies, Overnames

BBVA Says Sabadell Offer Remains in Effect

11 aug 2025, 16:26 UTC

Acquisities, Fusies, Overnames

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Announced TSB Sale on July 1

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Vergelijking

Prijswijziging

CorMedix Inc Prognose

Koersdoel

By TipRanks

86.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.75 USD 86.2%

Hoogste 20 USD

Laagste 17 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CorMedix Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan CorMedix Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

9.2 / N/ASteun & Weerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

30 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.